Clinical · Molecular biology
Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes
This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.